[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607180":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":72,"collaborators":74,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":78,"sex":84,"minAge":85,"maxAge":18,"enrollmentInfo":86,"targetDuration":18,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":100,"whyStopped":18,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Medical College of Wisconsin","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"High-risk Intervention","EXPERIMENTAL","Participants with high-risk sFlt-1\u002FPlGF ratio randomized to early detection and management of postpartum preeclampsia with remote blood pressure monitoring, education, and dispensing antihypertensive medication (nifedipine ER) for outpatient management of asymptomatic, mild range BP.",[13],"Other: Early detection and management of postpartum preeclampsia bundle",{"label":15,"type":16,"description":17,"interventionNames":18},"High-Risk Control","NO_INTERVENTION","Participants with high-risk sFlt-1\u002FPlGF ratio randomized to standard postpartum care.",null,{"label":20,"type":16,"description":21,"interventionNames":18},"Low-risk Control","Participants with low-risk sFlt-1\u002FPlGF ratio will not be randomized, but will remain enrolled to assess the exploratory outcome of biomarker predictive ability.",[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":18},"Early detection and management of postpartum preeclampsia bundle","Remote blood pressure monitoring, education, and dispensing antihypertensive medication (nifedipine ER) for outpatient management of asymptomatic, mild range BP.",[9],[28],{"name":29,"affiliation":5,"role":30},"Anna Palatnik, MD","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":18,"email":36},"Alyssa Hernandez, DO","CONTACT","4148055285","alyhernandez@mcw.edu",[38,56],{"facility":5,"status":18,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Milwaukee","Wisconsin","53226","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-87.90647,43.0389,{"lat":48,"lon":47},[51,54,55],{"name":29,"role":34,"phone":52,"phoneExt":18,"email":53},"414-805-6627","apalatnik@mcw.edu",{"name":33,"role":34,"phone":35,"phoneExt":18,"email":36},{"name":29,"role":30,"phone":18,"phoneExt":18,"email":18},{"facility":57,"status":18,"city":58,"state":18,"zip":18,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Dhulikhel Hospital","Dhulikhel","Nepal","NP",{"type":45,"coordinates":62},[63,64],85.54281,27.6221,{"lat":64,"lon":63},[67,71],{"name":68,"role":34,"phone":69,"phoneExt":18,"email":70},"Abha Shrestha, MD","0977-1-5522981","abhaobgy@kusms.edu.np",{"name":68,"role":30,"phone":18,"phoneExt":18,"email":18},{"type":30,"investigatorFullName":29,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Associate Professor",[75],{"name":57,"class":6},"100607180","postpartum-preeclampsia-early-detection-and-treatment-nepal-pilot-study-100607180",false,"NCT07185204","Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study","Postpartum Preeclampsia Early Detection and Treatment: Using Biomarkers to Implement Risk-stratified Intervention (Nepal Pilot Randomized Controlled Trial)","PREDiCT-NPL","Inclusion Criteria:\n\n* Pregnant patients ≥ 36 weeks gestation without major fetal anomalies\n* Age ≥ 18 years\n* Admitted for labor at Dhulikhel Hospital, or intend to deliver at Dhulikhel Hospital\n* At risk for preeclampsia, using the Clinical Risk Assessment for Preeclampsia according to ACOG and USPSTF\n\n  * 1 or more high risk factors:\n\n    * History of preeclampsia\n    * Type 1 or 2 diabetes\n    * Multifetal gestation?\n    * Renal disease\n    * Autoimmune disease\n  * 2 or more moderate risk factors:\n\n    * Nulliparity\n    * BMI \\> 30\n    * First-degree relative with a history of preeclampsia\n    * African American race\n    * Low socioeconomic status\n    * Age \\> 35 years\n    * History of low birthweight or small for gestational age\n    * Previous adverse pregnancy outcome\n    * Interpregnancy interval \\> 10 years\n\nExclusion Criteria:\n\n* Antenatal hypertensive disorder of pregnancy diagnosis, including gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines\n* Chronic hypertension, according to ACOG guidelines\n* Known allergy or contraindication to nifedipine\n* Inability or unwillingness to provide informed consent\n* Two or more blood pressures with an SBP ≥140 or DBP ≥90 after consent and prior to sFlt-1\u002FPlGF testing (screen failure criteria)","FEMALE","18 Years",{"count":87,"type":88},60,"ESTIMATED","INTERVENTIONAL",[91],"NA","The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1\u002FPlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia. High-risk participants will be randomized to a bundle of care strategies aimed at early detection and management of postpartum preeclampsia.",[94],"Postpartum Preeclampsia",[96,97,98,99],"Preeclampsia","Hypertension","Pregnancy","Postpartum","NOT_YET_RECRUITING","2026-03-12",{"date":103,"type":104},"2026-03-13","ACTUAL",{"date":106,"type":88},"2026-05",{"date":108,"type":88},"2027-05",{"name":5,"class":6},2]